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ABSTRACT
LIKABILITY AND EFFICACY OF GUMMY ORAL SEDATIVE BY PEDIATRIC
PATIENTS
DEGREE DATE: JUNE 30, 2019 Marisol Carbonell, D.M.D.
COLLEGE OF DENTAL MEDICINE NOVA SOUTHEASTERN UNIVERSITY
Judith Chin DDS, MS, Director, Pediatric Dental Residency Program, NSU College of
Dental Medicine

Background: Behavior guidance of the pediatric patient remains a challenge in
dentistry and may require pharmaceutical interventions. Midazolam and
hydroxyzine oral syrups are predictable and frequently used for in-office
sedations in pediatric dentistry. However, midazolam’s bitter taste and
hydroxyzine’s large volume make administration problematic for uncooperative
children. The purpose of this project was to compare the use of soft-chewable
gummies containing sedatives to the oral syrups currently used in conscious
sedation. The aim of this project was to administer midazolam and hydroxyzine in
gummy form and determine if this alternative vessel is as effective and better
liked by children undergoing sedation when compared to the respective oral
syrups.
Methods: Small-sized gummies containing 2.5 mg of midazolam or 5.0 mg of
hydroxyzine were optimized for taste masking and compounded at the NSU
pharmacy. A pilot study was conducted at NSU’s Joe DiMaggio Dental Clinic to
test the likability and the effectiveness of these gummies. A convenience sample
of 20 patients requiring conscious sedation were evaluated and determined eligible
to receive sedation by gummies for the test group. A cohort of 20 patients
vii

previously administered syrup sedatives served as the historical control. In both
groups, the sedative agent and dose were selected and calculated based on
patient specific parameters and anticipated duration of treatment. Sedation onset
time was recorded for each patient along with a score obtained from a hedonic
scale evaluating patients’ likability of the different medications.
Results: For the midazolam group, data obtained from the historic cohort, was
compared to the data obtained from the participants of the clinical trial. A small
sample size did not allow for categorizing patients based on demographics,
however there were no significant differences between both groups. The
midazolam gummy group had a greater frequency of higher hedonic scale
scores, however, the finding was not statistically significant. The onset time for
the midazolam gummy group was also slightly shorter, but also not statistically
significant. Results for the midazolam and hydroxyzine group are not available
due to insufficient data and low number of participants.
Conclusions: Oral sedation is an alternative method of behavior guidance used
by pediatric dentists. The targeted population often rejects the medication,
compromising the sedation. More favorable methods of administering
medications are necessary. Research using compounded medications and
clinical trials with the pediatric population must continue to optimize the final
product.

Key words: Oral Conscious sedation, Midazolam, Hydroxyzine, Pediatrics,
Gummy, Compounding
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CHAPTER 1 INTRODUCTION
1.1 Background
Behavior guidance of pediatric patients remains a challenge in dentistry. A
survey administered to US board certified pediatric dentists corroborated the
belief that changes in parenting styles have affected treatment modalities,
resulting in much less use of assertive behavior guidance techniques.1
Consequently, pharmaceutical techniques are frequently used to supplement
behavior guidance. Deep sedation or general anesthesia may be indicated for
cases requiring extensive treatment, while conscious sedations may be more
appropriate for in-office management of less extensive cases.

Although the oral medication route is predictable and practical for dental cases,
administration of oral sedative syrups is problematic for uncooperative children.
This problem is compounded by the fact that these medications can have a very
unpleasant taste (e.g., midazolam) or require a large volume to be swallowed in
meeting the dosing requirements (e.g., hydroxyzine). Therefore, a need exists to
develop and evaluate means for administration of sedative medications that can
overcome the problems with administration of the current liquid formulations.

1.2 Drug Selection/ Midazolam
Midazolam is currently the benzodiazepine of choice for in-office sedations in
pediatric dentistry. It was first introduced in 1976 by Fryer and Walser. 2 It is a
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selective CNS depressor which acts by opening GABA mediated chloride
channels. When compared to diazepam, which has active metabolites and a long
half-life, midazolam has a much shorter half-life and its metabolites have little to
no pharmacologic activity. After oral administration in children, midazolam is
rapidly absorbed and undergoes extensive metabolism in the liver, with an
elimination half-life of approximately 40-60 minutes. In dentistry, it is used
particularly for the therapeutic benefits of anterograde amnesia, anxiolysis,
sedation and hypnosis. Although it may cause respiratory depression, there is a
wide safety margin between a therapeutic dose and a toxic dose. 3 Midazolam is
a short-acting sedative agent with a high safety margin and a readily available
reversal agent, properties that make it suitable for the use of in-office conscious
sedations in pediatric dentistry. 2

1.3 Route of Delivery/ Midazolam
Midazolam is approved in United States for administration by the oral and
parenteral routes. Other off-label routes include intranasal, sublingual/buccal,
and rectal.

Intravenous: The administration of midazolam by parenteral routes bypasses the
extensive first pass metabolism effects of the liver and produces a rapid onset of
action (1.5 to 5 minutes) and a working time of 20-60 minutes. While the efficacy
of the IV route is known by many pediatric dentists, it is often not feasible with
children that suffer from dental anxiety and fear.

2

Intranasal: The administration of intranasal midazolam also bypasses the
extensive first pass metabolism effects of the liver. It has an onset time of 10-15
minutes and a working time of approximately 10-25 minutes. This method of
delivery is associated with ease of administration and compliance, requiring little
time for administration. However, studies show that 61-74% of patients will cry
during administration of intranasal midazolam.4 This discomfort felt by the child
may have an opposite effect and increase the patient’s anxiety.

Sublingual/Buccal: Midazolam is absorbed through the oral mucosal with onset of
action for the buccal cavity being approximately 20-30 minutes. These routes of
delivery have not found traction in the field of pediatric dentistry. The reasons
may be due to the fact that younger children often have trouble following
directions, especially when normal reflexes have to be overcome.4,5

Rectal: There is a discrepancy amongst studies in regards to the recommended
dose, ranging from 1 mg/kg to 0.25-0.35 mg/kg.2 6 Regardless, the child or parent
may find it uncomfortable or distressing to use this route, especially in a dental
setting. 6,7 For these reasons, rectal administration has not been embraced in the
US by pediatric dentists.

Oral: After oral administration, midazolam undergoes first pass metabolism,
reducing the bioavailability. Therefore, only 15% to 30% of a dose will reach the
systemic circulation. For this reason, the oral dose administered is higher
3

compared to other routes. Oral doses range from 0.3- 1.0 mg/kg and typically
have a slow onset of anxiolytic and sedative effects, occurring within 20-30
minutes.5 This route has other limitations for pediatric patients, for example, a
child may spit out all or most of the medication due to its unpleasant taste. Even
if the child swallowed most of it, the provider will likely not reach proper sedation
and will be unable to give a second dose due to the uncertainty of the ingested
amount. According to the American Academy of Pediatric Dentistry, the oral
route is the most accepted route by children.8 Therefore, for this study oral
administration was chosen as the preferred route.

1.4 Drug Select Hydroxyzine
Hydroxyzine is another common agent used in sedations because of its minimal
other drugs such as midazolam for longer in-office procedures.9 Hydroxyzine is a
first-generation antihistamine (H1 receptor antagonist) with sedative properties.10
It is commonly prescribed to children for allergic diseases with drowsiness and
decreased alertness (mild sedation) reported as a common side effect.9
Hydroxyzine also has antiemetic, antispasmodic and anticholinergic effects.
Although it has a wide safety margin, when used with other central nervous
system depressants it can enhance the depressant effect.11 Doses studied for
the use of sedation in the pediatric population range from 1-2 mg/kg.11 When
using the commercially available 10 mg/5 mL oral syrup, this can result in a large
volume of liquid for a pediatric patient to ingest.
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1.5 Current Limitations
There are three major limitations to using oral sedatives such as midazolam and
hydroxyzine in the pediatric population:

1. Aversion to Administration: Medications presented in a medicine cup or
oral syringe are often associated with anxiety and apprehension,
especially in uncooperative children. Several studies have reported a
positive correlation between the patient’s willingness to take the
medication, and the outcome of the sedation.11,12 Therefore, increasing
the acceptance of the medication may contribute to the success of the
sedation.

2. Aversion to Taste: Midazolam has bitter taste that is very difficult to mask.
Previously, it has been mixed with fruit juices, soda, or other flavored
drinks in an attempt to improve acceptance.13 However, children continue
to have difficulty swallowing the entire dose and a high level of rejection
persists with these prepared formulations.

3. Limited Dosage Forms in Pediatrics: The aversive taste of a medication
can be overcome by dispensing it in a tablet or capsule. However, children
often have difficulty with tablets and capsules because they cannot
swallow them properly and lack experience.14 Despite knowing this, there
continues to be few pediatric formulations to address administration
5

problems.15

1.6 Literature Review of Formulation Designs
The unpleasant taste of medications is one of the most common causes of noncompliance among pediatric patients for orally administered drugs.16 As such,
additional delivery methods have been studied to mask the taste of bitter
medications using pediatric-friendly dosage forms.

Intranasal: Intranasal formulations of midazolam have been used in an attempt to
avoid the bitter taste and increase acceptance rates. For example, Manoj et al.
compared the acceptance of oral versus intranasal midazolam.17 This study
reported that the oral liquid was more accepted by children, likely due to a
burning sensation from the nasal route.17

Oral: Recently, a hospital in Australia reported success in masking the bitter taste
of midazolam by compounding it with a chocolate base into chewable chocolate
tablets. 18 Similarly, Lenahan et al. reported higher acceptance rates for
hydroxyzine pills crushed and mixed with a flavoring agent. 11 However, the study
showed that approximately 11% of the time patients were still non-compliant.
They also reported success rates dropping significantly when a portion of the
medication was expectorated. Rosen and Rosen reported that the preferred
vehicle in their pediatric intensive care unit, operating room, and clinics at the
University of Michigan Medical Center was midazolam injection mixed with
6

flavored gelatin (with sugar) that was solidified in ice-cube trays. This method
was most favored by children compared to mixing the injection solution in
partially melted commercially available popsicles, orange juice, apple juice,
cherry and banana flavor extracts, chocolate syrup, crème de marshmallow, and
cola.19

1.7 Research Opportunity

Most of the research available for hydroxyzine or midazolam in the pediatric
population evaluates the efficacy of the drug as a sedative agent or evaluates
different routes of administration. In 2018, a study conducted by Cheung et al.
evaluated the palatability of midazolam compounded into chocolate tablets. In
this study, chocolate was used because of its ability to mask bitterness and
improve the presentations of the sedative. Rosen and Rosen reported that the
preferred vehicle in their pediatric intensive care unit, operating room, and clinics
at the University of Michigan Medical Center was midazolam injection mixed with
flavored gelatin (with sugar) that was solidified in ice-cube trays.19 However, to
our knowledge no previous research has evaluated midazolam or hydroxyzine
compounded into gummies.

There was also no research found in regard to NPO status when using gummy
medications. On this subject, Dr. Sandra Kaufman, a board-certified
anesthesiologist and Chief of Services for Pediatric OR at Joe DiMaggio
Children’s Hospital, was consulted. She stated she had no safety concern
7

involving the use of gummies prior to sedation. Dr. Jeff Browstein, a boardcertified pediatric dentist and dental anesthesiologist, was also consulted and
communicated that he also had no safety concerns over breaking NPO status
with the sedation gummies.

1.8 Research Goals and Objectives
For both sedatives, the main obstacle is the patient’s willingness and cooperation
to take the medication. In this study, the objective is to overcome these obstacles
with the help of compounding pharmacology by using gummies as a vessel. The
goal of this project is to develop effective midazolam and hydroxyzine gummies
that are palatable and therefore, easier to administer than the suspensions.

1.9 Specific Aims
In this study, we had 2 specific aims:
1. To determine children’s likability of midazolam and hydroxyzine gummies
used for sedation.
2. To evaluate sedation (efficacy) parameters after administration of
hydroxyzine and midazolam gummies by oral route.
1.10 Hypotheses
In this study, we tested the following hypotheses:
1. Whether medicated gummies are appealing, accepted, and liked by
children.
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2. Whether midazolam and hydroxyzine gummies provide onset times equal
to those in liquid form for children.
Null Hypotheses:
1. Medicated gummies are just as appealing, accepted, and liked by children
as the respective syrup forms of the medications.
2. Midazolam and hydroxyzine gummies provide onset times similar to those
in respective syrup form for children.
Alternative Hypotheses:
1. Medicated gummies are more appealing, accepted, and liked by children
than the respective syrup forms of the medications.
2. Midazolam and hydroxyzine gummies provide onset times different to those
in respective syrup form for children.

9

CHAPTER 2 MATERIALS AND METHODS
2.1 Materials
Hydroxyzine HCl and midazolam HCl gummies were compounded at the NSU
pharmacy using commercially available sources of the drugs or pharmaceutical
grade bulk powders (Figure 1). The drug doses were standardized in each gummy
(2.5 mg for midazolam and 5.0 mg for hydroxyzine) to meet the sedation needs of
patients based on weight using one or more gummies. The chewable gummy base
consisted of gelatin, simple syrup, flavoring, and sweetener. Bitter masking of the
drug in the formula was optimized using bitter suppressing agents, organic acids,
sodium salt and/or other known ingredients commonly known in the art of
compounding. The flavor used for the gummies was "Tutti Frutti".

Figure 1. Physical attributes of medicated gummy bears
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2.2 Method of Preparation
During preparation, the formula was melted and poured into molds resembling
bears. This process, known as fusion, allows the drug and other components to
dissolve or disperse in the melted base. The final product was a gummy bear
approximately 18 mm in length, 10mm in width, and 10mm in thickness (Figure
2). The color varied slightly for each medication.
Packaging: The gummies were individually wrapped in foiled paper and
packaged in a tight, light-resistant container.
Labeling: The label stated “use only as directed, store in refrigerator, must be
chewed before swallowing”.
Storage: The medication was stored in a locked refrigerator for medications only.
Refer to Appendix C for compounding procedures and Appendix D for a sample
of the compounding record used for documentation.

Figure 2. Gummy bear example
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2.3 Overall Study Design
The participation population of the study resulted from the convenience and
natural inflow of patients from NSU’s Pediatric Dental clinic at Joe DiMaggio
Children’s Hospital that needed sedation and from a historic cohort of previous
sedations done in the same clinic. The sedation check list was used to determine
if patients were sedation candidates (Appendix E). Parents were informed of the
medication vehicle during the sedation consultation and during the sedation
appointment. If they agreed to participate in this study, informed consent was
obtained. For patients 8 years old and older, assent was obtained.

Base line vitals (blood pressure and oxygen saturation) were obtained before
initiating the sedation. The participants were given the gummies containing the
sedative medication and instructed to chew the gummy before swallowing. The
sedation monitor observed the child chewing the gummy and recorded whether
the patient took the medication, partially took it, or did not take it at all. Only the
patients who took the medication were included in the study. After ingestion, the
patients were asked to rate the gummies using a five-point hedonic scale (Figure
3). Vitals were recorded at a 5-minute interval. The data collected for the
midazolam gummy group and the midazolam plus hydroxyzine gummy group
was compared to previous data collected using the respective syrup formulas.
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Figure 3. Hedonic scale

2.4 Monitoring of Sedation
If the patient refused to take the medicated gummies, the sedation continued with
the syrup form. Patients that partially ingested the gummies (e.g., spit a portion
out) were continuously monitored until all the discharge criteria was met
(Appendix F).
All patients in the study were monitored during the sedation in accordance to the
standard of care established by the American Academy of Pediatric Dentists. The
onset of sedation and continued levels of sedation were recorded on the sedation
record sheet by the attending pediatric dental faculty or resident every five
minutes, and were categorized as none, minimal, moderate, deep, or general
anesthesia. The level of sedation was determined by the patient’s
responsiveness in accordance to the Continuum of Depth of Sedation provided
by the American Society of Anesthesiologists.20

2.5 Selection of Sedative Agent
Selection of the sedative agent was based on the anticipated duration of
treatment, with midazolam usually used for short procedures (extractions, one to
13

two surface restorations, stainless steel crowns), and a combination of
midazolam plus hydroxyzine used for longer procedures (pulpotomies and
stainless-steel crowns, multiple quadrant dentistry).
The sedation dosage for midazolam in the study ranged from 0.23 to 0.5 mg/kg.
The sedation dosage for hydroxyzine ranged from 0.3 to 0.68 mg/kg. The
appropriate dosage for each individual was selected and the number of gummies
necessary was calculated.
Example:
A 0.5 mg/kg dose of midazolam for a child weighing 20 kg would be calculated as
follows:
20 kg x 0.5 mg/kg = 10 mg of midazolam
The corresponding number of individual gummies would be calculated as follows:
1 gummy = 2.5 mg midazolam/gummy
10 mg x (1 gummy/2.5 mg midazolam) = 4 gummies

2.6 Sample Size
Anticipated sample size: 40 patients
20 Sedation records where the liquid medication was used in the past (historic
cohort)
- 10 records of patients who used midazolam suspension
- 10 records of patients who used midazolam and hydroxyzine suspension
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20 New patients undergoing sedation using gummies
- 10 patients using the midazolam only gummy
- 10 patients using the midazolam and hydroxyzine gummies

2.7 Variables
Dependent Variables:
Acceptance of the midazolam and hydroxyzine liquid and gummies using the
five-point hedonic scale.
The effectiveness of the sedation with liquid and gummies using onset time.
Independent Variables:
The patient’s demographics (gender, age), dental history (number of sedations
for dental treatment), and the dosage of medication administered.

2.8 Criteria
Inclusion:
Patients who meet the criteria for oral sedation at NSU’s Joe DiMaggio Dental
Clinic using midazolam only or midazolam and hydroxyzine. These criteria
include:
•

Age: 3 years and older

•

Airway assessment score of no more than Brodsky 2, and Mallampati II

•

No limited neck mobility

•

No micro/retrognathia

•

No macroglossia
15

•

No obesity (patients with a BMI of 85% or less)

•

Patients who are ASA Class I or II

•

Indication for sedation such as fear, situational anxiety, uncooperative
behavior due to lack of maturity, physical or mental disability

•

English speaking

•

Charts reviewed for oral sedations using the syrup form of midazolam
only, or midazolam and hydroxyzine

•

Charts reviewed for patients who are ASA Class I or II

Exclusion:
•

Patient’s diagnosed with Autism Spectrum Disorder due to a similar study
being conducted with this specific population

•

Allergy or known hypersensitivity to any active or inactive ingredient in the
gelatin gummies

•

Charts reviewed that do not have a record of the hedonic scale

•

Charts reviewed where the hedonic scale was not adequately completed

16

Figure 4. Sedation protocol flowchart
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2.9 Statistical Analysis
Descriptive statistics were calculated for all study variables. Because these
metrics were not normally distributed, or possessed heterogeneity of variance,
nonparametric tests were conducted. To compare the acceptance of the
midazolam and hydroxyzine gummies and the effectiveness of the sedation with
syrup and gummies using onset time, a Van der Waerden test was conducted.
The advantage of the Van Der Waerden test is that it provides the high efficiency
of the standard ANOVA analysis when the normality assumptions are in fact
satisfied, but it also provides the robustness of the Kruskal-Wallis test when the
normality assumptions are not satisfied. JMP 14 SW used for all statistical
analysis. Statistical significance was accepted at p < 0.05.
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CHAPTER 3 RESULTS
3.1 Comparison of Midazolam Gummy and Midazolam Syrup

For this portion of the clinical study, data was collected from 10 records of
patients who had the midazolam syrup (historic cohort) and 10 patients who had
the midazolam gummy. Patient demographics are listed in Table 1.
Table 1. Analysis of the independent variables collected from 20 participants in the midazolam
portion of the clinical study

Midazolam Gummy
(n=10)
Age

Mean
SD

Gender

Dosage
mg/kg

# of
Sedations

Midazolam Syrup
(n=10)

6.00
1.76

P value
(<0.05)

5.70
1.05

0.6639

Male 6 (60%)
Female 4 (40%)

6 (60%)
4 (40%)

1.0000

Mean
SD.

0.385
0.100

0.8215

1(100%)

0.3292

0.363
0.073

1 (80%)
2 (10%)
3 (10%)

Due to the small sample size, the data was not categorized based on
demographics. However, there were no significant differences in any of the
demographic characteristics of the midazolam syrup group, versus the
midazolam gummy group. Table 2 summarizes the data collected for the hedonic
scale and onset time. A mosaic plot is provided as a visual illustration of the
results for the hedonic scores (Graph 1).
28

Table 2. Analysis of the dependent variables collected from 20 participants in the midazolam
portion of the clinical study

P value
(<0.05)

Onset Time
Minutes

Midazolam Gummy Midazolam Syrup
(n=10)
(n=10)
group
Mean 16.60
18.10
SD
5.78
7.05

Hedonic
Score (1-5)

Mean
SD

0.411

2.80
1.69

2.10
1.66

0.6639

Graph 1. Mosaic plot of the hedonic score and midazolam groups

Nonparametric Van der Waerden tests were conducted to compare the
acceptance and onset times for the midazolam groups. There was a preference
for the midazolam gummies, though it was not statistically significant (Graph 2).
The same test was conducted to compare the onset times. Although the gummy
group had a faster onset time, it was also not statistically significant.
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Graph 2. One-way analysis of variance box plots illustrating observed hedonic scores for
selected vehicles containing midazolam
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Graph 3. One-way analysis of variance box plots illustrating observed onset times by midazolam
in selected vehicles.

3.2 Comparison of Midazolam Plus Hydroxyzine Gummy and Midazolam
Plus Hydroxyzine Syrup

This portion of the study was intended compare the syrup and gummies used for
midazolam and hydroxyzine. However, there were an insufficient number of
patients (n=3) who received this treatment combination during the study
timepoints to obtain a complete data set. Table 3 summarizes the findings for the
3 patients that received this sedation.

Table 3. Data collected from 3 participants in the clinical study for the midazolam plus
hydroxyzine groups

Midazolam and Hydroxyzine
Gummy
Mean
11.0
(n=1)

Midazolam and Hydroxyzine
Syrup
Mean
9.5
(n=2)

Gender

Male
Female

Male
Female

Dosage
mg/kg

Mean Midazolam 0.30
Mean Hydroxyzine 0.30

Age

# of
Sedations

0 (0%)
1 (100%)

1 (50%)
1(50%)

Mean Midazolam
Mean Hydroxyzine.

1 (100%)

0.42
0.59

1 (100%)
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CHAPTER 4 DISCUSSION AND CONCLUSIONS
4.1 Discussion
The clinical study did not yield any statistically significant results, likely because of
the low number of participants. Recruiting participants for the midazolam plus
hydroxyzine group was difficult because of the low frequency in which both
medications are used together. As previously stated, midazolam and hydroxyzine
are used in conjunction for longer procedures. However, patients requiring
extensive treatment or complex procedures are more likely to be seen in the
operating room under general anesthesia.

Recruiting participants was also challenging due to issues such as appointment
cancellations or rescheduling due to health reasons (e.g., a recent upper
respiratory infection). Moreover, writing prescriptions for each patient, the time
necessary for making the gummy bears, transporting the gummy bears, and their
short beyond-use dating (2 weeks) added to the complexity and expense of the
study.

Although the data was not statistically significant, there was a trend of patients
liking the midazolam gummy bears more than the syrup. Anecdotally, the
participants also showed more enthusiasm and compliance prior to ingesting the
gummy bears in comparison with the syrup. Additionally, we noticed an added
benefit to the gummies which was clinically relevant and not anticipated at the
beginning: If the patient spit out the medicated gummy bear, it was easier to
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salvage, re-administer and continue with the sedation. With the syrup, if the patient
spit out a portion of the medication, the dose was usually lost on the patient napkin
or clothes. Since we are unable administer an additional dose, this could
compromise the success of the syrup sedation.

Another positive outcome was the efficacy of the medication. The sedation onset
times were very similar in comparison to the syrup. In fact, the gummy bears had
a slightly shorter onset time (statistically insignificant). This may be due to
increased solubility of the drug occurring from changes in local pH due to the acids
in the gummy formulation; since midazolam is more soluble at lower pH values
(e.g., <4). Another hypothesis is that the increased residence time in the mouth
during chewing may lead to a portion of the drug being absorption through the oral
mucosa.

Future clinical trials should streamline the process of ordering, making, and
transporting the gummies. A longer timeframe is also necessary to

recruit

participants for the midazolam and hydroxyzine groups. Also, higher number of
participants will help determine if the trends noted have statistical significance.

4.2 Conclusions
Oral sedation is an alternative method of behavior guidance frequently used by
pediatric dentists. The population requiring sedation is often very anxious or
uncooperative. Syrup medications are often rejected or spit out, compromising
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the success of the sedation. Therefore, it is necessary to formulate an
alternative sedation medication delivery system that is effective and better liked
by children undergoing sedation in comparison to the respective oral syrup.
Compounding medications to circumvent a bitter taste or large volume is a viable
alternative that must continue to be researched. Clinical trials with the pediatric
population are necessary to make necessary adjustments to the final product.
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CHAPTER 5 RAW DATA
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APPENDICES
Appendix A
Pharmacology Information Regarding Medicated Gummies written by Dr. David
Mastropietro

Classification
Chewable gummies fall under the lozenge category of dosage forms. Lozenges
are a type of solid or semi-sold dosage form that can be dissolved, disintegrated,
or chewed in the mouth. Varies types of lozenges have traditionally been used as
an alternative for the delivery of mediations to the oral mucosa (locally) and
systemically after being ingested. They are advantage for patients since they are
pleasantly flavored, sweetened, easily administered to those who have difficulty
swallowing, and can facilitate administration to geriatric and pediatric patients.21
They may also be considered more accurate for patient dosing when compared to
measuring liquid formulations. There are three types of lozenges: Hard, Soft, and
Chewable (gummy). It has been reported that gelatin gummy sweets and other
soft chewable dosage forms may be easier, more appealing and natural to chew
for children, compared to a chewable tablets.22

More recently, the term “Chewable Gels” has become the official nomenclature
according to the United States Pharmacopeia (USP) for soft chewable gummy
formulations designed to deliver drug substances or dietary supplements orally.
Bioactive components have also been studies for delivery in gelatin chewable
bases to help with taste and stability issues.23 There are now 2 official USP
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monographs developed for chewable gels and two more under development based
on USP recognizing the need and growing market for these formulations.24
USP Monographs for Chewable Gels
•

Ascorbic Acid Chewable Gels

•

Cholecalciferol Chewable Gels

•

Under Development
o Cyanocobalamin Chewable Gels (submitted May-JUN
2018)
o Oil-and Water-soluble Vitamins with Minerals Chewable
Gels

There are limited manufactured prescription products in gummy formulations (e.g.,
Vitafol Gummies). Although patents on soft chewable gummies containing
pharmaceutical ingredients are abundant.

Lozenges are also frequently compounded by pharmacies to meet specific needs
of patients not met by commercial products. Soft chewable lozenges are
compounded using a base of glycerinated gelatin; a mixture of glycerin, gelatin,
and water that was adapted from the popular gelatin suppository based (20%
gelatin, 70% glycerin, and 10% water).
Compounded Chewable Gummy Formulations and Bases
(selected list published in the International Journal of Pharmaceutical
Compounding)
•

Fentanyl 50-mcg Chewable Gummy Gels
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(Jan/Feb 2000)

•

Lorazepam 1-mg Chewable Gummy Gels

(Jan/Feb 2001)

•

Fentanyl 50-mcg Chewable Gummy Gels

(Mar/Apr 1998)

•

Pediatric Chewable Gummy Gel Base

(Mar/Apr 1997)

•

Pediatric Chewable Gummy Gels

(Mar/Apr 1997)

Despite their popularity and use, published drug dissolution and bioavailability
studies are lacking in the literature. Dille et al. reported dissolution studies of a soft
gelatin chewables containing either ibuprofen, acetaminophen, or meloxicam.25
Results of each formulation showed drug release was comparable in dissolution
studies when compared to standard tablet formulations of the same medication.
The formulations also exhibited good drug stability for up to 24 months. Hattrem et
al. conducted bioavailability studies of the ibuprofen chewable formulation and
showed comparable bioavailable to the commercially available tablet dosage
form.26 This strongly suggests that the gelatin matrix of the formulation does not
affect normal pharmacokinetics. The median time for peak serum concentrations
reported after 3 chews and 8 chews were 1.25 and 1.75 hours, respectively. This
was in comparison to a commercially available hard tablet at 1.5 hours. Since
ibuprofen solubility is low (21 mg/L in water) the rate limiting step to absorption is
drug dissolution. In contrast, midazolam HCl has high water solubility at low pH
(>2 mg/mL in water) and will be readily absorbed. Therefore, the rate limiting step
should be the dissolution of the gummy formulation. Our preliminary study shows
complete dissolution of the gelatin gummies within 15 minutes. Additional
information is provided in the Appendix A.
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Bioavailability
The compounded gummy bears have a formulation intended to provide an
environment of maximum drug solubility and release after ingestion. For example,
the aqueous solubility of midazolam hydrochloride is greatest at low pH. More
specifically, a pH below 4 would ensure adequate solubility for a formulation
concentrated at 2 mg/mL.27 Our gummy formulation base (with no drug) provides
a low pH environment (pH 3.2, experimentally determined) with an organic acid
buffering system of citric and malic acid. Additionally, the midazolam injection that
is added to our base formulation during compounding has an adjusted pH 3. Since
our gummies have a midazolam concentration of approximately 1.67 mg/mL there
should be adequately soluble at the pH of the final formulations to ensure rapid
dissolution and drug absorption. The formulation also contains other highly watersoluble components including sucrose (simple syrup) that rapidly dissolve in
gastric juices and help form pores in the gummy that facilitate drug release and
gelatin dissolution. Midazolam has also been reported to be absorbed
transmucosal in the mouth from the buccal cavity28, but with the limited residual
time of the gummies in the mouth this is less significant.

In our case, the dissolution of the gelatin gummy and release of the drug can be
considered the rate limiting step to oral absorption. Since midazolam is rapidly
absorbed after oral administration29, the faster the gelatin is dissolved the more
rapid we should be drug absorption. Our gummy formulations have gelatin that is
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already hydrated with water and further promotes an environment for fast
dissolution of water-soluble drugs and the gelatin. The gelatin matrix used in the
gummies have a so-gel transition temperature range of 28-31.5oC, very much
below physiologic conditions (37oC), to promotes disintegration and dissolution
during the start of mastication. The low melting temperature also allows quick
dissolution in the gastrointestinal tract. Dissolution studies of fully intact gummy
bear formulation demonstrated full drug release within 15 minutes. Chewing the
gummy bear into pieces would be expected to enhance this rate. Further
information regarding our studies are provided in the Appendix A.

Stability
A 14 day beyond-use date (expiry date) was placed for the compounded gummy
preparations. This is based on USP <795> beyond-use dating for aqueous oral
preparations in the absence of stability data. Since no direct stability studies have
been performed on our compounded gummy formulation, we are relying on several
studies that support our 14 days as being very conservative. These studies are
listed below in figure 1. In summary, midazolam HCl injection is preserved and
stable when diluted with various parenteral admixtures for over 14 days at room
temperature and when subjected to high autoclaving temperatures (121oC for 30
minutes). When midazolam HCl injection is compounded and mixed with oral
liquids for ingestion, it was stable for 14 days (some up to 102 days) with no signs
of microbial growth, color, turbidity, pH, or odor. When mixed with gelatin (Jell-O),
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midazolam HCl was also shown to be stable for 14 days refrigerated, and 28 days
when frozen.

SUMMARY OF PUBLISHED STABILITY STUDIES (MIDAZOLAM HCl)
PARENTERAL COMPOUNDED PREPARATIONS
TITLE
SUMMARY
Chemical stability of De Diego et al. 30 reported the stability of parenteral
midazolam injection
solutions of midazolam are very stable undiluted and
by high performance when diluted in 5% dextrose even when exposed to light
liquid
and room temperature conditions for over 14 days.
chromatography.
Photochemical
Andersin et al.31 reported Midazolam injection was also
decomposition of
shown to be physically and chemically stable in the more
midazolam iv. Study complex aqueous environment of parenteral nutrition
of pH-dependent
solutions for at least 5 hours; study did not evaluate
stability by highstability past this time. Although solutions of midazolam
performance liquid
are relatively stable, the lower the pH, the greater
chromatography
stability from photodegradation.
Extended stability of Trissel and Hassenbush27 reported compounded
compounded
midazolam solutions (2.5-5 mg/mL) in sodium chloride
preservative-free
solutions (0.9%, 0.45%) were stable for three months
midazolam (as
when stored at 4,23, and 37 oC. Autoclaving the solution
hydrochloride)
(121oC for 30 minutes) showed little or no loss of
injection
midazolam content.
ORAL COMPOUNDED FORMULATIONS
Stability of parenteral Walker et al. 32 The chemical and physical stability of an
midazolam in an oral oral solution of midazolam made by mixing parenteral
formulation
midazolam HCl solution with orange fruit flavored syrup
was investigated using stability indicating methods.
Results of this study showed solutions at a concentration
of 0.35,0.64 and 1.03 mg/ml were stable and showed no
appreciable degradation (<6.5%) at room temperature
(23oC) over a 102 day period (when the study ended).
The syrup was packaged in polyethylene containers and
prepared by adding 30 mL of distilled water to 50 mL of
simple syrup and then adding 0.12 mL of pure orange
extract with shaking. One drop each of red and yellow
food coloring was added, and additional distilled water
was incorporated to bring the volume to 100 mL. The
midazolam hydrochloride injection was added to yield
the test concentrations.
Stability of
Steedman et al. 33 The stability of an extemporaneously
midazolam
prepared 2.5-mg/mL solution of injectable midazolam
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hydrochloride in a
flavored, dye-free
oral solution

HCl in a flavored dye-free syrup Syrpalta (1:1 ratio) was
stable for 56 days at 7, 20, or 40 degrees C when stored
in 1 oz amber glass bottles. There was also no visible
signs of microbial growth, color, turbidity or odor
observed through the same time period.

Making oral
midazolam palatable
for children

Peterson34 Mixed midazolam injection in serpalata syrup,
apple juice, and various carbonated beverage before
settling on a concentrated grape Kool-Aid sweetened
with Nutrasweet. More specifically, the concentrate was
made by mixing a 2-quart package of Kool-Aid with 2
cups of water. The appropriate dose of midazolam (5
mg/mL injection) was then mixed with 5-10 mL of this
concentrate. Driscoll Foundation Children’s Hospital in
Texas.
Gregory et al. 35 The stability of midazolam HCl injection
was investigated when mixed in syrup (Simple Syrup,
NF) and flavored with peppermint oil to yield a
concentration of 2.5 and 3 mg/mL. Results showed
midazolam concentrations were minimally decreased
and less than 10% loss for up to 14 days when stored in
glass amber bottles at room temperature.

Stability of
midazolam prepared
for oral
administration

Stability of an oral
midazolam solution
for premedication in
paediatric patients

Soy et al. 36 A extemporaneously prepared 1 mg/mL oral
midazolam HCl solution was shown to be stable with no
changes in pH for up to 60 days when stored at room
temperature. The oral solution was made by mixing
midazolam injection solution (5 mg/mL) with sodium
saccharin, flavor drops (lemon or strawberry), and
purified water. The oral solution contained 20 mL of
midazolam hydrochloride (5 mg/mL), saccharin sodium
240 mg, lemon or strawberry flavor, and purified water
80 mL.

A palatable gelatin
vehicle for
midazolam and
ketamine

Rosen and Rosen19 suggested the liquid from a partially
melted commercially available popsicle, orange juice,
apple juice, cherry and banana flavor extracts, chocolate
syrup, crème de marshino, and cola. The preferred
vehicle in pediatric intensive care unit, operating room,
and clinics at the University of Michigan Medical Center
was flavored gelatin sweetened with sugar. Gelatin was
made in ice cube trays prepared by adding 1.3 mL of
gelatin to every 1 mL of drug. Cubes were made of 5, 10,
or 15 mg and cut into proportions for fractional doses.
Geiger et al.37 reported the stability of midazolam HCl
oral suspension (1 mg/mL) prepared from the injection
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Stability of
midazolam in

SyrSpend SF and
SyrSpend SF Cherry

and mixed with a commercial suspending and flavoring
liquid combination (i.e., SyrSpend SF and SyrSpend SF
Cherry). The suspension showed little to no loss on
midazolam HCL content for 58 days when stored at
ambient room temperature or refrigerated (2-8oC) in lowactinic prescription bottles.
GUMMY (GELATIN) COMPOUNDED PREPARATIONS
Stability of
Bhatt-Mehta et al. 38 reported the stability of midazolam
midazolam
HCL in flavored gelatin (Jell-O; Kraft Foods) at a
hydrochloride in
concentration of 1-2 mg/mL. No loss of midazolam was
extemporaneously
shown to occurred for samples stored under refrigeration
prepared flavored
(4oC) at 14 days and stored frozen (-20oC) for 28 days.
The preparation was made by adding 30 or 90 mL of
gelatin
midazolam injection (5 mg/mL) to 120 mL to 135 mL of
freshly prepared liquid gelatin for a 1-mg/mL or 2 mg/mL
concentration. Additionally, no change in color or odor
occurred, and no evidence of bacterial growth was
observed. The liquid was then packaged in unit-dose
cups containing 5 mg/5 mL and 15 mg/7.5 mL,
respectively. The preparations were reported to be sweet
but produced a bitter aftertaste that was more intense for
the 2 mg/mL concentration.
Midazolam gelatin
Allen LV reported39,40 the preparation of midazolam in a
cubes for children
gelatin base (Jell-O) prepared by adding 1 mL of
midazolam injection (5 mg/mL) to 1.3 mL of a prepared
gelatin solution and placing into ice-cube trays or other
suitable molds. The gelatin base was prepared by mixing
6 Fl. oz of boiling water with a 3 oz package of flavored
gelatin and allowed to cool before mixing with
midazolam. A beyond use date of 14 days was provided
based on USP; no other reference given.

Table 1. Summary of Published Stability Studies (Midazolam HCL)
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Appendix B
Pharmacology Experiments conducted by Dr. David Mastropietro
Sol-gel Temperature (Gummy Melting Temperature)
Experimental Procedure: A 50 mL beaker with water and was placed in
the center of a hotplate with an empty 25 mL beaker sitting inside it. A
blank gummy (no drug) sample was placed into the 25 mL beaker and a
digital thermometer rested inside. The temperature of the hotplate was
increased slowly allowing equilibrium of temperature to the sample
gummy. Temperature was recorded at the first visual sign of melting
and again at complete melting of gummy. This temperature range served
as the sol-gel transition range.
Results: Onset of melting and free-flowing of the sample was initiated at
28oC. Complete melting and loss of viscosity was seen at 31.5oC
pH Test
Experimental Procedure: A blank gummy (no drug) sample weighing
approximately 1.7-1.8 g was placed into a 25 mL beaker and 10 mL of
distilled water was added. Under constant stirring the sample was
heated to approximately 55oC until all of the sample was dissolved. The
solution was then allowed to cool to 25oC before pH measurement was
performed using a SympHony B10P benchtop meter.
Results: Measurement of pH was performed at 25oC with a stable
reading of 3.20.
Dissolution Test
Experimental Procedure: Compounded gummies containing 2.5 mg of
hydroxyzine HCl were made and allowed to solidify for 6 hours under
refrigeration. Based on compendial methods for hydroxyzine HCl tablets,
gummies were then subjected to dissolution studies using a USP 2
Paddle method in 900 mL of distilled water at 37.oC ±0.5oC and a paddle
rotational speed of 50 rpm. Hydroxyzine HCl concentration in the
dissolution medium was analyzed over time. Aliquots withdrawn for
analysis were replaced with equal volumes of fresh dissolution media at
37 °C. The concentration of hydroxyzine HCl in dissolution media was
obtained using UV-Visible Spectroscopy on a PerkinElmer LAMBDA™
365 instrument set at 230 nm. All extracts were passed through a 0.2
micron filter prior to analyses. To determine drug concentration, a
calibration curve was constructed using drug solutions of known
concentration. A linear calibration curve (absorbance against
concentration) was obtained by plotting a minimum of 5 points covering
the concentration range of interest and checked for linearity (r2=0.999).
Chemical interference from gelatin was observed with our testing
method in the absorbance peak being measured resulting in slightly
higher values being reported from our calibration curve in water.
Reference samples containing dissolved blank gelatin gummy at equal
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[Hydroxyzine HCl]
µg/mL

time points were therefore used as a baseline to minimize spectral
overlap.
Results: Dissolution data showed drug release occurred rapidly with the
full dose being released within 15 minutes.
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Appendix C
Compounding Procedures written by Dr. David Mastropietro
In addition to established quality standards of the pharmacy, the
compounding record (CR) serves as the documentation ensuring the
accuracy and completeness of each compounded preparation. According
to USP <1168> written procedures should include details of the materials,
equipment and procedures use that can be easily replicated. Records
should also exit for compounding, packaging, storage.
A sample of the compounding record is in Appendix B.
In particular, the CR record for the gummy records:
• The compound name, strength, and amount prepared
• All ingredients, grades, and quantities used
o Name, manufacturer, and lot number of each raw material
used
This also provides ingredient tracking for any potential
ingredient recalls
Certificates of Analysis are also reviewed for each bulk
raw material
o Name, strength, volume or quantity of each ingredient
measured (2 person verified)
Ingredients used are stored in a clean dry area,
adequately labeled, and handled using procedures to
minimize and prevent contamination/cross-contamination
• Stability & Assignment of beyond-use-date (expiry date)
o 14 days under refrigerated conditions [Based on USP <795>
and published stability studies]
• Equipment
o Document of equipment used in compounding
Both disposable and electromechanical
Prescription balance calibration verification is performed
using standard weights after balance cleaning and prior
to weight measurements.
• Calculations
• Preparatory procedures
o Each step is standardized to ensure a consistent preparation
that is reproducible
Descriptions include equipment used in the compounding
process
• Packaging and Storage Requirements
o Packaging is in a tight, light resistant amber prescription
bottle container
Protects the preparation adequality from the environment
and transport
• Quality Control (Final Check)
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o According to the draft guidance of USP <1168> Compounding
for Phase I Investigational Studies, the evaluation of one or
more quality attributes (e.g., physical, chemical, and
microbiological testing) should be performed before the
investigational preparation is released. Compounded solid oral
dosage forms can undergo physical QC tests to ensure the
uniformity and accuracy of compounded preparations. These
tests address individual dosage unit weights (including the
average), total preparation weight, pH, and physical attributes
such as appearance, taste, and smell.
For our compounded gummies, at the completion of
compounding, physical characteristics (uniformity, clarity,
odor, color, hardness) of the gummies are assessed to
ensure they are consistent with those established.
Additionally, the finished gummies are weighted to
ensure they fall within ± 10% of the calculated individual
dose weight.
The results of these quality control tests are documented
as shown in the Compounding Record section.
Additionally, quality assurance (QA) measures are
incorporated in the compounding process (i.e., weight
measurements checked by 2 individuals) to ensure that
the actual yield matches the theoretical yield of finished
preparation. Any deviations will be accounted for,
documented, and not dispensed.
A final check is also performed by a second Pharmacist
employed by the pharmacy who reviews the
compounding record to ensure the procedures and
techniques used were faithfully followed and
appropriately documented before dispensing on the
order of the prescription.
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Appendix D
Sample Compounding Record
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Appendix E
Pre- Sedation Checklist
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Appendix F
Sedation Record
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